Qingdao Baheal Medical (301015) Fundamentals 2026 — P/E 23.8x, Revenue Analysis | SniperIQ
Qingdao Baheal Medical (301015) is a CN-listed Healthcare company in Drug Manufacturers - General with a market capitalization of ¥12.4B, trading at ¥23.51 on the SHZ. This SniperIQ fundamentals page covers Qingdao Baheal Medical's valuation (P/E 23.8x, P/B 4.7x), profitability (net margin 6.9%), revenue (¥7.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Qingdao Baheal Medical's market cap?
Qingdao Baheal Medical (301015) has a market capitalization of approximately ¥12.4B, trading at ¥23.51 on the SHZ. Market cap moves with the live share price.
What is Qingdao Baheal Medical's P/E ratio?
Qingdao Baheal Medical's trailing twelve-month P/E ratio is 23.8x, with a price-to-book (P/B) of 4.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Qingdao Baheal Medical?
Qingdao Baheal Medical runs a net profit margin of 6.9%, a gross margin of 38.4%, and an operating margin of 10.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Qingdao Baheal Medical generate?
Qingdao Baheal Medical reported revenue of ¥7.5B for fiscal year 2025, with net income of ¥475M and earnings per share (EPS) of 0.9. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Qingdao Baheal Medical pay a dividend?
Qingdao Baheal Medical offers a trailing dividend yield of about 2.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Qingdao Baheal Medical financially healthy?
Qingdao Baheal Medical carries a debt-to-equity ratio of 1.44x and a current ratio of 1.43x, with a market beta of 0.42. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Qingdao Baheal Medical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Qingdao Baheal Medical (301015) the key facts are: market cap ¥12.4B, P/E 23.8x, revenue ¥7.5B, 52-week range 18.4-32.38. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Qingdao Baheal Medical's full fundamentals live
Get Qingdao Baheal Medical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.